688331.SS
Price:
$62.82
Market Cap:
$31.60B
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, S...[Read more]
Industry
Biotechnology
IPO Date
2022-03-31
Stock Exchange
SHH
Ticker
688331.SS
According to RemeGen Co Ltd’s latest financial reports and current stock price. The company's current ROE is -62.50%. This represents a change of 298.02% compared to the average of -15.70% of the last 4 quarters.
The mean historical ROE of RemeGen Co Ltd over the last ten years is 12.90%. The current -62.50% ROE has changed -584.33% with respect to the historical average. Over the past ten years (40 quarters), 688331.SS's ROE was at its highest in in the September 2019 quarter at 49.25%. The ROE was at its lowest in in the June 2020 quarter at -57.65%.
Average
12.90%
Median
-19.41%
Minimum
-73.93%
Maximum
185.49%
Discovering the peaks and valleys of RemeGen Co Ltd ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 242.31%
Maximum Annual ROE = 185.49%
Minimum Annual Increase = -350.20%
Minimum Annual ROE = -73.93%
Year | ROE | Change |
---|---|---|
2024 | -73.93% | 68.15% |
2023 | -43.97% | 119.22% |
2022 | -20.06% | -350.20% |
2021 | 8.02% | -141.29% |
2020 | -19.41% | -110.47% |
2019 | 185.49% | 242.31% |
The current ROE of RemeGen Co Ltd (688331.SS) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-45.98%
5-year avg
-29.87%
10-year avg
12.90%
RemeGen Co Ltd’s ROE is
Company | ROE | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like RemeGen Co Ltd using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like RemeGen Co Ltd or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is RemeGen Co Ltd's ROE?
How is the ROE calculated for RemeGen Co Ltd (688331.SS)?
What is the highest ROE for RemeGen Co Ltd (688331.SS)?
What is the 3-year average ROE for RemeGen Co Ltd (688331.SS)?
What is the 5-year average ROE for RemeGen Co Ltd (688331.SS)?
How does the current ROE for RemeGen Co Ltd (688331.SS) compare to its historical average?